Search

Your search keyword '"Jones, C. Elaine"' showing total 23 results
Start Over Author "Jones, C. Elaine"
23 results on '"Jones, C. Elaine"'

4. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial

Author

Day, Nicola C., Kumar, Subramanya, Criner, Gerard, Dransfield, Mark, Halpin, David M. G., Han, MeiLan K., Jones, C. Elaine, Kaisermann, Morrys C., Kilbride, Sally, Lange, Peter, Lomas, David A., Martin, Neil, Martinez, Fernando J., Singh, Dave, Wise, Robert, and Lipson, David A.

Published
2020
Full Text
View/download PDF

5. A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial

Author

Bafadhel, Mona, primary, Barnes, Neil, additional, Bourke, Stephen C., additional, Compton, Chris, additional, Criner, Gerard J., additional, Dransfield, Mark T., additional, Halpin, David M.G., additional, Han, MeiLan K., additional, Hartley, Benjamin, additional, Jones, C. Elaine, additional, Lange, Peter, additional, Lettis, Sally, additional, Lipson, David A., additional, Lomas, David A., additional, Martin, Neil, additional, Martinez, Fernando J., additional, Wise, Robert, additional, and Singh, Dave, additional

Published
2021
Full Text
View/download PDF

6. Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT

Author

Dransfield, Mark T., primary, Crim, Courtney, additional, Criner, Gerard J., additional, Day, Nicola C., additional, Halpin, David M. G., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, LaFon, David, additional, Lipson, David A., additional, Lomas, David A., additional, Martin, Neil, additional, Martinez, Fernando J., additional, Singh, Dave, additional, Wise, Robert A., additional, and Lange, Peter, additional

Published
2021
Full Text
View/download PDF

7. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD

Author

Hanania, Nicola A., primary, Mannino, David M., additional, Criner, Gerard J., additional, Dransfield, Mark T., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lomas, David A., additional, Martin, Neil, additional, Martinez, Fernando J., additional, Singh, Dave, additional, Wise, Robert A., additional, Halpin, David M.G., additional, Lima, Robson, additional, and Lipson, David A., additional

Published
2021
Full Text
View/download PDF

8. InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions

Author

Bourdin, Arnaud, primary, Criner, Gerard, additional, Devouassoux, Gilles, additional, Dransfield, Mark, additional, Halpin, David M.G., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kalhan, Ravi, additional, Lange, Peter, additional, Lettis, Sally, additional, Lipson, David A., additional, Lomas, David A., additional, Echave-Sustaeta María-Tomé, José M., additional, Martin, Neil, additional, Martinez, Fernando J., additional, Quasny, Holly, additional, Sail, Lynda, additional, Siler, Thomas M., additional, Singh, Dave, additional, Thomashow, Byron, additional, Watz, Henrik, additional, Wise, Robert, additional, and Hanania, Nicola A., additional

Published
2021
Full Text
View/download PDF

9. InforMing the PAthway of COPD Treatment Single-Inhaler Triple Therapy (Fluticasone Furoate/ Umeclidinium/ Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium /Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions

Author

Bourdin, Arnaud, Criner, Gerard, Devouassoux, Gilles, Dransfield, Mark, Halpin, David M.G., Han, Meilan, Jones, C. Elaine, Kalhan, Ravi, Lange, Peter, Lettis, Sally, Lipson, David, Lomas, David, Echave-Sustaeta María-Tomé, José, Martin, Neil, Martinez, Fernando, Quasny, Holly, Sail, Lynda, Siler, Thomas, Singh, Dave, Thomashow, Byron, Watz, Henrik, Wise, Robert, Hanania, Nicola, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, Université de Lyon, Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama, College of Medicine and Health, University of Exeter Medical School, University of Exeter, Exeter, Pulmonary and Critical Care, University of Michigan, Ann Arbor, Michigan, GlaxoSmithKline, Research Triangle Park, North Carolina, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Department of Public Health, University of Copenhagen, Copenhagen, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, Penn Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, UCL Respiratory, University College London, London, Respiratory Department, Hospital Universitario Quirónsalud Madrid, Universidad Europea de Madrid, Madrid, GlaxoSmithKline, Brentford, Middlesex, Weill Cornell Medicine [New York], GlaxoSmithKline, Glaxo Smith Kline, Midwest Chest Consultants, PC, St Charles, Missouri, The University of Manchester, Manchester University National Health Service Foundation Trust, Division of Pulmonary, Allergy, and Critical Care, Columbia University Medical Center, New York, New York, Pulmonary Research Institute at Lungen Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, Section of Pulmonary and Critical Care Medicine, Airways Clinical Research Center, Baylor College of Medicine, Houston, Texas, MORNET, Dominique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), University of Exeter, and University of Copenhagen = Københavns Universitet (UCPH)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

10. The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population

Author

Kato,Motokazu, Tomii,Keisuke, Hashimoto,Kenichi, Nezu,Yasuko, Ishii,Takeo, Jones,C Elaine, Kilbride,Sally, Gross,Annette S, Clifton,Christine S, and Lipson,David A

Subjects
International Journal of Chronic Obstructive Pulmonary Disease
Abstract

Motokazu Kato,1 Keisuke Tomii,2 Kenichi Hashimoto,3 Yasuko Nezu,3 Takeo Ishii,4 C Elaine Jones,5 Sally Kilbride,6 Annette S Gross,7 Christine S Clifton,7 David A Lipson8,9 1Chest Disease Clinical and Research Institute, Kishiwada City Hospital, Kishiwada, Japan; 2Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan; 3Evidence Generation Department, GlaxoSmithKline K.K., Tokyo, Japan; 4MA Respiratory Department, GlaxoSmithKline K.K., Tokyo, Japan; 5Development, R&D, GlaxoSmithKline, Research Triangle Park, NC, USA; 6Biostatistics, GlaxoSmithKline, Uxbridge, Middlesex, UK; 7Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline R&D, Sydney, Australia; 8Clinical Sciences, GlaxoSmithKline, Collegeville, PA, USA; 9Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USACorrespondence: Yasuko NezuEvidence Generation Department, Respiratory Medical Affairs & Development GlaxoSmithKline K.K., Akasaka Intercity AIR 1-8-1 Akasaka, Minato-Ku, Tokyo 107-0052, JapanTel +81 3 4231 5064Fax +81 3 4231 5994Email yasuko.2.nezu@gsk.comPurpose: The Informing the Pathway of COPD Treatment (IMPACT) study demonstrated that single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduces moderate/severe exacerbation rates and improves lung function and health status versus FF/VI or UMEC/VI dual therapy in patients with symptomatic COPD and a history of exacerbations. This analysis evaluated the efficacy and safety of FF/UMEC/VI in patients enrolled in Japan.Patients and methods: IMPACT was a 52-week, randomized, double-blind, multicenter study comparing FF/UMEC/VI 100/62.5/25 μg with FF/VI 100/25 μg or UMEC/VI 62.5/25 μg in patients ≥40 years with symptomatic COPD and ≥1 moderate/severe exacerbation in the previous year. Endpoints included annual rate of on-treatment moderate/severe exacerbations (primary endpoint), time-to-first on-treatment moderate/severe exacerbation and change from baseline at Week 52 in trough FEV1, post-bronchodilator FEV1, St. George’s Respiratory Questionnaire, and COPD Assessment Test score. Safety was also assessed.Results: The Japan subgroup accounted for only 4% (378/10,355) of the overall IMPACT intent-to-treat (ITT) population. In the Japan subgroup, FF/UMEC/VI reduced the annual rate of on-treatment moderate/severe exacerbations by 15% (95% CI: −20, 40) versus FF/VI (compared with 15% [10, 20] in the ITT) and 36% (95% CI: 6, 57) versus UMEC/VI (compared with 25% [19, 30] in the ITT). FF/UMEC/VI reduced moderate/severe exacerbation risk (time-to-first), improved lung function and health status at Week 52 versus both dual therapies. These results were in the same direction and of a generally similar magnitude to those seen in the overall ITT population. No new safety signals were identified in the Japan subgroup compared with the ITT population. Pneumonia incidence was higher with FF/UMEC/VI and FF/VI versus UMEC/VI.Conclusion: These results highlight the favorable benefit–risk profile of FF/UMEC/VI single-inhaler triple therapy compared with FF/VI or UMEC/VI dual therapy in patients in Japan with symptomatic COPD and ≥1 exacerbation in the prior year.Keywords: triple therapy, fluticasone furoate, Japan, umeclidinium, vilanterol, COPD exacerbation

Published
2019

11. Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial

Author

Halpin, David M. G., primary, Criner, Gerard J., additional, Dransfield, Mark T., additional, Han, MeiLan K., additional, Hartley, Benjamin, additional, Harvey, Catherine, additional, Jones, C. Elaine, additional, Kato, Motokazu, additional, Lange, Peter, additional, Lettis, Sally, additional, Lomas, David A., additional, Martinez, Fernando J., additional, Martin, Neil, additional, Singh, Dave, additional, Wise, Robert, additional, Zheng, Jinping, additional, and Lipson, David A., additional

Published
2020
Full Text
View/download PDF

12. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial

Author

Han, MeiLan K., primary, Criner, Gerard J., additional, Dransfield, Mark T., additional, Halpin, David M. G., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lettis, Sally, additional, Lipson, David A., additional, Lomas, David A., additional, Martin, Neil, additional, Wise, Robert A., additional, Singh, Dave, additional, and Martinez, Fernando J., additional

Published
2020
Full Text
View/download PDF

13. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

Author

Lipson, David A., primary, Crim, Courtney, additional, Criner, Gerard J., additional, Day, Nicola C., additional, Dransfield, Mark T., additional, Halpin, David M. G., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lomas, David A., additional, Lettis, Sally, additional, Manchester, Pamela, additional, Martin, Neil, additional, Midwinter, Dawn, additional, Morris, Andrea, additional, Pascoe, Steven J., additional, Singh, Dave, additional, Wise, Robert A., additional, and Martinez, Fernando J., additional

Published
2020
Full Text
View/download PDF

14. The effect of exacerbation history on outcomes in the IMPACT trial

Author

Halpin, David M.G., primary, Dransfield, Mark T., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lipson, David A., additional, Lomas, David A., additional, Martinez, Fernando J., additional, Pascoe, Steve, additional, Singh, Dave, additional, Wise, Robert, additional, and Criner, Gerard J., additional

Published
2020
Full Text
View/download PDF

16. Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?

Author

Bafadhel, Mona, primary, Barnes, Neil, additional, Bourke, Stephen, additional, Compton, Chris, additional, Criner, Gerard, additional, Dransfield, Mark, additional, Halpin, David, additional, Han, Meilan, additional, Hartley, Benjamin, additional, Jones, C. Elaine, additional, Lange, Peter, additional, Lettis, Sally, additional, Lipson, David, additional, Lomas, David, additional, Martin, Neil, additional, Martinez, Fernando, additional, Van Der Valk, Ralf, additional, Wise, Robert, additional, and Singh, David, additional

Published
2019
Full Text
View/download PDF

17. The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time

Author

Lipson, David A, primary, Criner, Gerard, additional, Dransfield, Mark, additional, Halpin, David, additional, Han, Meilan, additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lomas, David, additional, Martinez, Fernando, additional, Quasny, Holly, additional, Singh, David, additional, and Wise, Robert, additional

Published
2019
Full Text
View/download PDF

18. The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints

Author

Han, MeiLan K., primary, Criner, Gerard, additional, Dransfield, Mark, additional, Halpin, David, additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lomas, David, additional, Martinez, Fernando, additional, Quasny, Holly, additional, Singh, David, additional, Wise, Robert, additional, and Lipson, David, additional

Published
2019
Full Text
View/download PDF

19. Misinterpretation of time-to-first event curves can lead to inappropriate treatment

Author

Hartley, Benjamin, primary, Criner, Gerard J., additional, Dransfield, Mark T., additional, Halpin, David M.G., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lipson, David A., additional, Lomas, David A., additional, Martin, Neil, additional, Martinez, Fernando J., additional, Singh, Dave, additional, Wise, Robert A., additional, and Lettis, Sally, additional

Published
2019
Full Text
View/download PDF

20. FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial

Author

Singh, Dave, primary, Barnhart, Frank, additional, Brealey, Noushin, additional, Criner, Gerard, additional, Dransfield, Mark, additional, Halpin, David M G, additional, Han, Meilan K, additional, Jones, C Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lomas, David A, additional, Martinez, Fernando J, additional, Mouneimne, Dalal, additional, Wise, Robert, additional, and Lipson, David A, additional

Published
2018
Full Text
View/download PDF

21. Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT

Author

Dransfield, Mark, primary, Crim, Courtney, additional, Criner, Gerard, additional, Halpin, David, additional, Han, Meilan, additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lipson, David, additional, Lomas, David, additional, Martinez, Fernando, additional, Singh, David, additional, and Wise, Robert, additional

Published
2018
Full Text
View/download PDF

22. Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening

Author

Singh, Dave, primary, Criner, Gerard, additional, Day, Nicola C., additional, Dransfield, Mark, additional, Halpin, David M.G., additional, Han, Meilan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lipson, David A, additional, Lomas, David A., additional, Pascoe, Steve, additional, Tabberer, Maggie, additional, Wise, Robert, additional, and Martinez, Fernando J., additional

Published
2018
Full Text
View/download PDF

23. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

Author

Lipson, David A., primary, Barnhart, Frank, additional, Brealey, Noushin, additional, Brooks, Jean, additional, Criner, Gerard J., additional, Day, Nicola C., additional, Dransfield, Mark T., additional, Halpin, David M.G., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lomas, David A., additional, Martinez, Fernando J., additional, Singh, Dave, additional, Tabberer, Maggie, additional, Wise, Robert A., additional, and Pascoe, Steven J., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results